Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.
暂无分享,去创建一个
C. Christiansen | P. Delmas | B. Mitlak | P D Delmas | W. Huster | C Christiansen | W J Huster | B H Mitlak | N. Bjarnason | A. Ravoux | A. Shah | M. Draper | N H Bjarnason | A C Ravoux | A S Shah | M Draper | N. Bjarnason | C. Christiansen | P. Delmas | Anne-Catherine Ravoux | Aarti Shah
[1] I. Cohen,et al. Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. , 1994, Gynecologic oncology.
[2] C. Turner,et al. Raloxifene preserves bone strength and bone mass in ovariectomized rats. , 1994, Endocrinology.
[3] S. Ortolani,et al. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. , 1995, Bone.
[4] C. Christiansen,et al. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. , 1997, Circulation.
[5] W. Huster,et al. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. , 1997, American journal of obstetrics and gynecology.
[6] M. Sporn,et al. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. , 1996, Journal of the National Cancer Institute.
[7] M. Karvonen,et al. Effect of cholesterol-lowering diet on mortality from coronary heart-disease and other causes. A twelve-year clinical trial in men and women. , 1972, Lancet.
[8] I. Reid,et al. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. , 1995, The American journal of medicine.
[9] D. Williams,et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. , 1994, The Journal of clinical investigation.
[10] T. Powles,et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] P. Delmas,et al. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[12] Susan R. Johnson,et al. Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial , 1995 .
[13] P. Armitage,et al. Repeated Significance Tests on Accumulating Data , 1969 .
[14] H. Genant,et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. , 1993, The American journal of medicine.
[15] G A Colditz,et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. , 1995, The New England journal of medicine.
[16] C. Arnaud,et al. A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[17] P. Delmas,et al. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. , 1993, The Journal of clinical endocrinology and metabolism.
[18] R. Heaney,et al. Raloxifene and estrogen: comparative bone-remodeling kinetics. , 1997, The Journal of clinical endocrinology and metabolism.
[19] B. Efron,et al. The Jackknife Estimate of Variance , 1981 .
[20] P. Delmas,et al. Measurement of serum osteocalcin with a human‐specific two‐site immunoradiometric assay , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[21] A. Glasebrook,et al. Identification of an Estrogen Response Element Activated by Metabolites of 17β-Estradiol and Raloxifene , 1996, Science.
[22] M. Klag,et al. Plasma lipoprotein levels as predictors of cardiovascular death in women. , 1993, Archives of internal medicine.
[23] N. Weiss,et al. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women , 1997, The Lancet.
[24] J. Shao. Consistency of jackknife variance estimators jun , 1991 .
[25] K. Kerlikowske,et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. , 1995, Obstetrics and gynecology.
[26] C. Christiansen,et al. Immunoassay for quantifying type I collagen degradation products in urine evaluated. , 1994, Clinical chemistry.
[27] Charles David Jones,et al. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. , 1983, Life sciences.
[28] T. Bourne,et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial , 1994, The Lancet.